.jpg)
.png)
Once again, welcome to our region. From the endless smooth coastline of California to the pristine and rocky Oregon and Washington coasts. From the best snow in the world in Utah and Idaho to the big sky country of Montana. From Nevada and the last frontier of Alaska to the idyllic dreamscape of Hawaii. From the 4,900 miles that our region covers, we welcome you.
Article By:
President, Pacific Lipid Association
University of California-Irvine Medical Center
California Heart Associates
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology
There are many new influences on how dyslipidemia is managed today. While this is exciting, as is common with change, there are cogs in the wheel of progress. Healthcare providers and patients are aware of barriers for implementing therapies that appear to be efficacious for optimal care. Multiple factors are involved with this issue.
Article By:
President, National Lipid Association
Consultative Education Specialist
Cardiovascular Risk Intervention
University of Pennsylvania Health System – Retired
Philadelphia, PA
Diplomate, Accreditation Council for Clinical Lipidology
Amgen announced today that the FOURIER trial met its primary and secondary endpoints in evaluating whether evolocumab reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) without new safety issues. Amgen also announced that the EBBINGHAUS trial revealed no difference in cognitive function between evolocumab and placebo. Detailed results will be released at the American College of Cardiology meeting in March.
Registration Now Open for Spring CLU
Register for the National Lipid Association’s Spring Clinical Lipid Update February 24–26, 2016, at the Hyatt Regency Phoenix. Don’t miss featured sessions on: New Paradigms for Cardiovascular Prevention, Familial Combined Hypercholesterolemia, and many more. Make sure to check lipid.org/springclu for updated agenda information and to register.
NLA Call for Abstracts
Article By:
David Neff, DO, has worked closely with the National Lipid Association and its members since 2003, and now volunteers his time as a member to help carry out its mission. Dr. Neff’s interest in lipidology originated from a research assignment that focused on cholesterol fed rodents with fatty liver during his undergraduate career at Michigan State University. While at Merck & Co. from late 2000 until 2014, Dr. Neff supported several cardiovascular brands in hypertension and lipids.
Article By:
Michigan State University
Michigan Department of Health & Human Services
The Midwest Lipid Association (MWLA) — alongside the Southwest Chapter — was proud to organize the 2016 Spring Clinical Lipid Update in San Diego this past March. The meeting was well-attended and very favorably reviewed. It featured an excellent faculty presenting talks on novel research in clinical lipidology as well as practical applications of lipid management.
Article By:
President, Midwest Lipid Association
Donald and Patricia Garofalo Chair in Preventive Cardiology
Professor of Medicine
University of Minnesota
Director Lipid Clinic
Cardiology, MHealth
Minneapolis, MN
Ms. K is an 83-year-old female who presents to clinic for a second opinion regarding management of cardiac risk factors. She first presented to clinic two years ago with chest pain and shortness of breath, both at rest and with exertion. Her medical history included hypertension and hyperlipidemia but no prior cardiovascular disease (CVD) and no smoking history nor diabetes. Her medications included daily aspirin 81mg, lisinopril 10mg, and metoprolol tartrate 25mg twice daily (BID).
Article By:
Cardiovascular Division
University of Minnesota
Minneapolis, MN
President, Midwest Lipid Association
Donald and Patricia Garofalo Chair in Preventive Cardiology
Professor of Medicine
University of Minnesota
Director Lipid Clinic
Cardiology, MHealth
Minneapolis, MN
Most coronary heart disease occurs in those over the age of 65.1 Statins reduce cardiovascular morbidity and mortality in both primary and secondary prevention.
Article By:
West County Personalized Medical Care
St. Louis, MO
While there is evidence for atherosclerotic cardiovascular risk reduction with statins in both primary and secondary prevention in older patients, there is a higher incidence of associated muscle symptoms and discontinuation because of those symptoms.1-3 Thus, consideration of the risk-benefit ratio of statins in older patients is recommended.4
Article By:
Clinical Pharmacist, Medication Management
Park Nicollet Health System
St. Louis Park, MN
Diplomate, Accreditation Council for Clinical Lipidology
Atherosclerosis is a lipid-driven disorder and the main underlying cause of cardiovascular disease (CVD).1 Microbiology has long been a critical focal area of medicine in terms of the effect of bacterial organisms on health and disease. What is the contemporary view of the relationship between these two aspects of clinical medicine?
Article By:
Physician Advisor and Medical Director for Chronic Disease Management
Wheaton Franciscan Healthcare All Saints
Racine, WI
Diplomate, American Board of Clinical Lipidology